Oral non-peptide GLP-1 receptor agonist studied for weight loss and glucose control. Phase III trials ongoing.

📖 Read the full Orforglipron research overview →

Evidence Tier: Tier 2 — Clinical Trials · Peptidings Verdict: Reasonable Bet